Research of Endobronchial Optical Coherence Tomography in Pre-COPD
Launched by SICHUAN PROVINCIAL PEOPLE'S HOSPITAL · May 30, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new technique called endobronchial optical coherence tomography (OCT) to help doctors better diagnose a condition known as Pre-COPD, which is an early stage of Chronic Obstructive Pulmonary Disease (COPD). Early detection of Pre-COPD is important because it can lead to better management and prevention of COPD, a serious lung disease that makes it hard to breathe. The researchers believe that this advanced imaging technique can provide valuable information to identify patients who might be at risk.
To participate in this trial, you need to be a non-smoker aged 65 to 74 with normal lung function and no serious lung diseases other than a small pulmonary nodule found on a chest CT scan. Unfortunately, individuals who cannot undergo a procedure called bronchoscopy, those taking part in other studies, or pregnant women cannot join. If eligible, you can expect to undergo some tests that will help researchers see how well this new method works in diagnosing Pre-COPD. Your participation could help improve diagnosis and treatment for many people in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • non-smoking with normal lung function, no other pulmonary diseases besides pulmonary nodule as indicated by chest computed tomography (CT).
- Exclusion Criteria:
- • (1) patients with contraindication of bronchoscopy, (2) patients who are participating in other clinical studies, (3) patients with poor compliance who are believed by the researchers to be unable to cooperate for the completion of the examination and follow-up, and (4) women who were pregnant.
About Sichuan Provincial People's Hospital
Sichuan Provincial People's Hospital is a leading healthcare institution in China, dedicated to advancing clinical research and improving patient care through innovative medical practices. With a robust infrastructure and a multidisciplinary team of experts, the hospital conducts a wide range of clinical trials aimed at evaluating new therapies and treatment modalities. Its commitment to high ethical standards and patient safety ensures that all research activities contribute valuable insights to the medical community, while fostering an environment of collaboration and excellence in healthcare delivery.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chengdu, Sichuan, China
Patients applied
Trial Officials
Guanghong G Zhou, Master
Study Director
Sichuan Provincial People's Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported